- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Given that cancer is ultimately a genetic disease, it has long been the hope of researchers to use gene therapy to attack tumors where they might be most susceptible. Those prospects have taken a significant step forward with the report that a trans-European research team has developed a nanoparticle that transports antitumor genes selectively to cancer cells. The technique, which leaves healthy cells unaffected, could offer hope to people with difficult-to-treat cancers. Although it has so far been tested only in mice, the researchers hope for human trials in 2 years.
Reporting its work in the journal Cancer Research, the research team, headed by Georges Vassaux, Ph.D., Institute National de la Santé et de la Recherche Médicale (INSERM), used poly(propylene imine) dendrimers as carriers for the genes. This particular dendrimer forms stable complexes with DNA that only appear to fall apart when inside tumor cells.
Once taken up by cancer cells, the genes enclosed in the nanoparticles force the cell to produce proteins that can kill the cancer. In this study, the cells were forced to make a protein known as the Na/I symporter, which was then visible in whole-body scans of the mice. These scans revealed that the transfected gene was expressed in cancer cells but not at an observable level in healthy cells.
"Gene therapy has a great potential to create safe and effective cancer treatments, but getting the genes into cancer cells remains one of the big challenges in this area. This is the first time that nanoparticles have been shown to target tumors in such a selective way, and this is an exciting step forward in the field," said Andreas Schatzlein, Ph.D., University of London, one of the investigators involved in the study. "Once inside the cell, the gene enclosed in the particle recognizes the cancerous environment and switches on. The result is toxic but only to the offending cells, leaving healthy tissue unaffected."
This work is detailed in the paper "Cancer-specific transgene expression mediated by systemic injection of nanoparticles." Investigators from the Queen Mary's School of Medicine and Dentistry in London, The London National Health Service Trust, Cancer Research United Kingdom, Instituto Aragonés de Ciencias de la Salud in Spain, and the University of Bordeaux in France also participated in this study. An abstract of this paper is available at the journal's Web site.
About NCI Alliance for Nanotechnology in Cancer
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
Copyright © NCI Alliance for Nanotechnology in CancerIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information